title: [L-acetylcarnitine treatment on fragile X patients hyperactive behaviour].
abstract: Hyperactivity is a significant problem for almost all young males affected by fragile X syndrome (FXS), the most common inherited disease causing mental retardation. Therapeutical approaches are actually based on Central Nervous System (CNS) stimulants lacking a well defined rationale and efficacy while they further decrease the patient's limited attention span. A pilot study on 17 fragile X male treated with L-acetylcarnitine (LAC) over one year, showed a significant reduction of their hyperactivity behaviour tested by the Conners Abbreviated Parent-Teacher Questionnaire. LAC use in FXS patients derives from the hypothesis that the biochemical and physiological properties this substance has may preserve brain activity. LAC is a small, hydrosoluble molecule that easily diffuses in the extracellular space and enters any cell in the nervous system through specific transporters. Different cerebral areas use this molecule differently to metabolize glucose and lipids to provide for ATP and neurotrasmitters synthesis. The acetyl group LAC carriers represents a key metabolic signaling element possibly mediating its effect in the CNS. The exogenous administration of LAC may affect brain activity in FXS by: I) modulation of fuel partitioning for energy production, which at the mithocondrial level is associated with the Kreb's cycle metabolic role in neurotransmitter synthesis; II) remodelling of lipid membrane in terms of LAC actively determining the production of polyunsaturated fatty acids; III) preferential effect on the attention component of the cholinergic system which relies on its peculiar modality of communication in the CNS. Based on the above premises an explorative, double-blind, placebo controlled, multicenter study is ongoing. A total population of 160 children from nine European centers will be enrolled. The objective of this study is to determine the effect of LAC on the hyperactive behaviour of FXS children as evaluated by the administration of the Conners Abbreviated Parent Questionnaire.
authors.affiliation: Departamento Científico, Sigma-Tau S.p.A., Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Calvani
authors.forename: S
authors.initials: S
authors.lastname: D'Iddio
authors.forename: A
authors.initials: A
authors.lastname: de Gaetano
authors.forename: P
authors.initials: P
authors.lastname: Mariotti
authors.forename: L
authors.initials: L
authors.lastname: Mosconi
authors.forename: M G
authors.initials: MG
authors.lastname: Pomponi
authors.forename: E
authors.initials: E
authors.lastname: Tabolacci
authors.forename: M G
authors.initials: MG
authors.lastname: Torrioli
authors.forename: S
authors.initials: S
authors.lastname: Vernacotola
authors.forename: G
authors.initials: G
authors.lastname: Neri
mesh_terms: D000108:Acetylcarnitine / Q000737:chemistry / Q000627:therapeutic use*; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005600:Fragile X Syndrome / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D015394:Molecular Structure; D009483:Neuropsychological Tests; D010865:Pilot Projects
chemical_list: D000108:Acetylcarnitine